Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.

Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, Chevallier O, Duvillard L, Vergès B

The Journal of clinical endocrinology and metabolism1 Feb 2017Cited by 168 (Europe PMC)

PMID27732328DOI10.1210/jc.2016-2775PepBankPUB-27732328

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with uncontrolled type 2 diabetes, 6 months of liraglutide was associated with a 31% relative reduction in liver fat content.
In plain wordsIn people with uncontrolled type 2 diabetes, liver fat fell by 31% after 6 months of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseLiver fat content change
Study
n = 68
Outcome group
Liver fat and liver function · Liver
Studied dose
1.2 mg/d · 6 monthsAs given in this study (human).
Measurements
Relative reduction in liver fat content
31%
liraglutide
Source sentences
Summary
a marked relative reduction in LFC of 31% (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
LFC was measured by proton magnetic resonance spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus.
Report a problemFND-2773232801
02HumanNon-randomized trialEfficacy outcome
In patients with uncontrolled type 2 diabetes, liraglutide was associated with a significant decrease in body weight.
In plain wordsIn people with uncontrolled type 2 diabetes, body weight fell during liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 68
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
Treatment with liraglutide was associated with a significant decrease in body weight, HbA1C, and a marked relative reduction in LFC of 31% (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
LFC was measured by proton magnetic resonance spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus.
Report a problemFND-2773232802
03HumanNon-randomized trialEfficacy outcome
In patients with uncontrolled type 2 diabetes, liraglutide was associated with a significant decrease in HbA1C.
In plain wordsIn people with uncontrolled type 2 diabetes, HbA1c fell during liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n = 68
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
Treatment with liraglutide was associated with a significant decrease in body weight, HbA1C, and a marked relative reduction in LFC of 31% (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
LFC was measured by proton magnetic resonance spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus.
Report a problemFND-2773232803
04HumanNon-randomized trialOther
In patients with uncontrolled type 2 diabetes treated with liraglutide, the reduction in liver fat content correlated with the reduction in body weight (r = 0.490).
In plain wordsIn people with type 2 diabetes on liraglutide, bigger weight loss was linked to bigger liver fat loss.
Peptide
Liraglutide
Outcome
Not applicableCorrelation of LFC reduction with weight reduction
Study
n = 68
Outcome group
Liver fat and liver function · Liver
Studied dose
1.2 mg/d · 6 monthsAs given in this study (human).
Measurements
Correlation r
0.49
LFC vs body weight reduction
Source sentences
Summary
The reduction in LFC and body weight were highly correlated (r = 0.490; P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
LFC was measured by proton magnetic resonance spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus.
Report a problemFND-2773232804
05HumanNon-randomized trialOther
In multivariate analysis of patients treated with liraglutide, the reduction in liver fat content was independently associated with baseline liver fat content.
In plain wordsIn people with type 2 diabetes on liraglutide, higher liver fat at the start was linked to a bigger drop in liver fat.
Peptide
Liraglutide
Outcome
Not applicableBaseline LFC as predictor of LFC reduction
Study
n = 68
Outcome group
Liver fat and liver function · Liver
Studied dose
1.2 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
In multivariate analysis, the reduction in LFC was independently associated with baseline LFC (P < 0.0001), age (P = 0.010), and reduction in body weight (P < 0.0001), triglycerides (P = 0.019), and HbA1c (P = 0.034).
1 context sentence(design, population, supporting numbers)
Summary · context
LFC was measured by proton magnetic resonance spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus.
Report a problemFND-2773232805
06HumanNon-randomized trialOther
In multivariate analysis of patients treated with liraglutide, the reduction in liver fat content was independently associated with age.
In plain wordsIn people with type 2 diabetes on liraglutide, age was linked to the size of the drop in liver fat.
Peptide
Liraglutide
Outcome
Not applicableAge as predictor of LFC reduction
Study
n = 68
Outcome group
Liver fat and liver function · Liver
Studied dose
1.2 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
In multivariate analysis, the reduction in LFC was independently associated with baseline LFC (P < 0.0001), age (P = 0.010), and reduction in body weight (P < 0.0001), triglycerides (P = 0.019), and HbA1c (P = 0.034).
1 context sentence(design, population, supporting numbers)
Summary · context
LFC was measured by proton magnetic resonance spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus.
Report a problemFND-2773232806
07HumanNon-randomized trialOther
In multivariate analysis of patients treated with liraglutide, the reduction in liver fat content was independently associated with the reduction in body weight.
In plain wordsIn people with type 2 diabetes on liraglutide, bigger weight loss was linked to a bigger drop in liver fat.
Peptide
Liraglutide
Outcome
Not applicableWeight reduction as predictor of LFC reduction
Study
n = 68
Outcome group
Liver fat and liver function · Liver
Studied dose
1.2 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
In multivariate analysis, the reduction in LFC was independently associated with baseline LFC (P < 0.0001), age (P = 0.010), and reduction in body weight (P < 0.0001), triglycerides (P = 0.019), and HbA1c (P = 0.034).
1 context sentence(design, population, supporting numbers)
Summary · context
LFC was measured by proton magnetic resonance spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus.
Report a problemFND-2773232807
08HumanNon-randomized trialOther
In multivariate analysis of patients treated with liraglutide, the reduction in liver fat content was independently associated with the reduction in triglycerides.
In plain wordsIn people with type 2 diabetes on liraglutide, a bigger fall in triglycerides was linked to a bigger drop in liver fat.
Peptide
Liraglutide
Outcome
Not applicableTriglyceride reduction as predictor of LFC reduction
Study
n = 68
Outcome group
Liver fat and liver function · Liver
Studied dose
1.2 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
In multivariate analysis, the reduction in LFC was independently associated with baseline LFC (P < 0.0001), age (P = 0.010), and reduction in body weight (P < 0.0001), triglycerides (P = 0.019), and HbA1c (P = 0.034).
1 context sentence(design, population, supporting numbers)
Summary · context
LFC was measured by proton magnetic resonance spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus.
Report a problemFND-2773232808
09HumanNon-randomized trialOther
In multivariate analysis of patients treated with liraglutide, the reduction in liver fat content was independently associated with the reduction in HbA1c.
In plain wordsIn people with type 2 diabetes on liraglutide, a bigger fall in HbA1c was linked to a bigger drop in liver fat.
Peptide
Liraglutide
Outcome
Not applicableHbA1c reduction as predictor of LFC reduction
Study
n = 68
Outcome group
Liver fat and liver function · Liver
Studied dose
1.2 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
In multivariate analysis, the reduction in LFC was independently associated with baseline LFC (P < 0.0001), age (P = 0.010), and reduction in body weight (P < 0.0001), triglycerides (P = 0.019), and HbA1c (P = 0.034).
1 context sentence(design, population, supporting numbers)
Summary · context
LFC was measured by proton magnetic resonance spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus.
Report a problemFND-2773232809
10HumanNon-randomized trialEfficacy outcome
In patients treated with liraglutide who had no significant decrease in body weight, no significant reduction in liver fat content was observed.
In plain wordsIn people on liraglutide whose weight did not fall significantly, liver fat did not fall significantly either.
Peptide
Liraglutide
Outcome
No significant changeLFC change in patients without weight loss
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
1.2 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
In the patients who had no significant decrease in body weight, no significant reduction in LFC was observed.
1 context sentence(design, population, supporting numbers)
Summary · context
LFC was measured by proton magnetic resonance spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus.
Report a problemFND-2773232810

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT03590626

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Medanta, The Medicity, Indian = 601 Jan 2019 to 18 Feb 2020

Non Alcoholic Fatty Liver Disease · Type2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 20 Feb 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.